Phone: 866-310-7549 M-F 8AM-8PM ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax# 866-441-4190

Novo Nordisk Maine State Insulin Affordability Program



The Novo Nordisk Maine State Insulin Affordability Program provides medication to qualifying applicants at no charge. If the applicant qualifies under the Maine State guidelines, up to a 120-day supply of the requested medication(s) or device(s) will be shipped to the patient.

Eligibility Requirements

You may qualify if:

- You are a resident of Maine and can provide one of the following:
 - Valid Maine driver's license or permit
 - Valid Maine identification card
 - Valid tribal identification card from a Maine tribe

or

- If the person who needs insulin is under the age of 18, the parent or legal quardian must provide proof of residency
- You are not enrolled in Medicaid or low-cost health insurance sponsored by the state (Maine Cares)
- · You are not eligible to receive prescription drug benefits through federally funded programs, with the exception of Medicare Part D
- · You are not enrolled or eligible to receive prescription drug benefits through the Department of Veterans Affairs
- If you have private prescription drug coverage, your out-of-pocket cost for a 30-day supply of insulin is greater than \$75
- Your total household income is at or below 400% of the federal poverty level (FPL) (NeedyMeds website lists current FPL guidelines)

What to send?

- Completed application (signed and dated by both patient and prescriber)
- · Proof of income
- · Copy of Maine driver's license or permit/identification card/Tribal card

IMPORTANT

- · Sign and Date ALL applicable sections.
- Ensure ALL *required fields have been completed.
- Include **ALL** required supporting documentation.
- Mail/Fax completed application & copies of required income documentation.

Any missing/incomplete/illegible information may cause a delay in processing.

Questions?

Phone: 866-310-7549 Monday-Friday 8AM-8PM ET

Fax: 866-441-4190

Patients: NovoPAP.com HCPs: NovoPAPHCP.com

What to Expect Next?

- Mail/Fax completed application & required income documentation.
- Allow 2 business days for processing.
- Enrollment decision will be sent via mail/fax to patients and healthcare providers.
- · Once approved, patients will receive a phone call to schedule delivery of medication to their home.
- Approved uninsured patients will be enrolled for 12 months. Medicare Part D patients are enrolled through the end of the calendar year and will need to reapply after October 15th for the following year.

Refills: Health Care practitioners must request all refills by submitting a refill/change request form, available at www.NovoPAPHcp.com. This form can be submitted 80 days prior to the next refill due date.

Phone: 866-310-7549 M-F 8AM-8PM ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax# 866-441-4190

Novo Nordisk Maine State Insulin Affordability Program



Check one: New Application

Re-Enrollment

Asterisks indicate required field. Do not leave blank.

PΔ	TI	EN	IT	SE	СТ	IO	N

Patient First Name*:	Last Name*:	Patient DOB*:
Patient's Street Address* (NO PO BOX):		·
City:		State: Zip:
Home Phone*:	Mobile Phone*:	
Gender: Male Female Prefer not to disclose	Email:	
Insurance		
Do you have any form of prescription drug coverage*?	TIF YES, please check ALL that apply	and complete information below. YES NO
Plan Name:	Member ID:	Phone#
Employer-supplied or commercial/private drug cove	rage VA or Militai	ry Benefits
Medicare Prescription Drug Coverage	-	escription Drug Coverage
(include a copy of the front and back of your card)	Medicare Lo	w Income Subsidy (LIS/Extra Help)
Medicare Part B (medical benefit that covers some prescription	<u> </u>	
Not sure if you have Medicare Rx coverage? Medicare Part D l Medicare Advantage Plans with prescription coverage also have		mewhere on the card.
Patient Authorized Representative (Optional)		
You may provide the name of an individual (i.e., spouse, sibling, child, etc.) wh the Novo Nordisk PAP. Those people who you authorize to speak to Novo Nordi advocacy groups as a patient-authorized representative. Novo Nordisk PAP is r without permission. Patients are not required to use a third party who charges	om you authorize Novo Nordisk Patient Assistanc isk PAP about you may provide or receive your pe oot affiliated with third parties who charge a fee f s a fee to help with enrollment or refills.	e Program to speak with on your behalf about your participation in rsonal information as necessary. Novo Nordisk does not accept paid or help with enrollment. These third parties may reference Novo Nordisk
Yes, I would like to authorize a person to speak on my If yes, please provide name, phone number and relationship be	y behalf. No, I do not want anyo	ne speaking to Novo Nordisk PAP on my behalf.
Authorized Representative Name:	Authorized Represent	ative phone number:
Family member/caregiver Other		
Patient Signature:		Date:
To remove an authorized representative, please call Novo Nordisk PAP a	t 1-866-310-7549	
Fair Credit Reporting Act (FCRA) Consent		
You have the option to allow PAP to perform an electronic incor	ne verification to process your applicat	on.
Please check here if you wish to choose this option and not	send in your income documents as note	d on the Instructions Page.
I understand that I am providing "written instructions" under ton an ongoing basis as needed for the duration of my participa profile or other information from the vendor through e-income qualifications for programs administered by PAP. I understand process. I promise that any information, including financial and provide additional documentation and that additional eligibility.	tion in programs administered by Novo e verification which will include a soft cri that I must affirmatively agree to these d insurance information that I provide, i	Nordisk PAP, to obtain information from my credit edit check, solely for the purpose of determining financial terms in order to proceed in this financial screening s complete and true. I also understand that I may need to
If you do not consent to an electronic income verification	n, please complete the information	n below and provide proof of income.
Total Household Annual Income \$		
# of people living in your household* (include yourself, spouse/partner, all adults)	# of dependents (u	ınder 18 years of age)*
Patient Medicare Prescription Drug Cover	age (Part D) Enrollee Cons	sent (if applicable)
I (or my parent/guardian/legal representative) agree that if I am may give my (or the patient's) Personal Information to the Cente enrollment status and let CMS and my (or the patient's) Medicarunderstand that upon approval, I (or the patient) will receive up year. I (or my parent/guardian/legal representative) agree that I Medicare Part D prescription plan while receiving them from PAI program or third-party insurer; and (iii) and will not apply any PAI	(or the patient is) approved for PAP as a srs for Medicare & Medicaid Services ("CN e Part D plan know of this enrollment in to a 120-day supply of the medication(s) (or the patient): (i) will not seek the requ P; (ii) am not eligible for reimbursement	Medicare Part D Enrollee, that Novo Nordisk or PAP //S") to confirm my (or the patient's) Medicare Part D PAP. Further, I (or my parent/guardian/legal representative) and/or device(s) from PAP through the end of this calendar ested Novo Nordisk medication(s) from my (or the patient's) for any medication dispensed by PAP from any government

Signature required ONLY if patient is a Medicare Part D enrollee Member Number/ID#*:

PAP Application Enrollment Year:

Patient or Parent/Guardian/Legal Representative Signature:

SIGNATURE REQUIRED

Phone: 866-310-7549 M-F8AM-8PM ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax# 866-441-4190

Novo Nordisk Maine State Insulin Affordability Program



PATIENT SECTION (continued)

Asterisks indicate required field. Do not leave blank.

		•			•			•	
и.		10	m	 m	TA	rm	ıat	\mathbf{I}	n
г	aı		111	 911	ıv		ıaı	ıv	

	ast Name*:	Patient DOB*:
--	------------	---------------

HIPAA Authorization

By signing below, I (or my parent/guardian/legal representative) hereby give permission for my (or the patient's) health care providers, pharmacies, service providers and their contractors, health plans, and health insurer(s) and their contractors, to disclose any and all necessary information, including, but not limited to, my (or the patient's) income, prescription coverage, medical prescriptions, medical condition, financial documents, and health records ("Personal Information") to the Novo Nordisk's Patient Assistance Program (collectively, "PAP"). This Personal Information aids PAP in medical condition, financial documents, and health records ("Personal Information") to the Novo Nordisk's Patient Assistance Program (collectively, "PAP"). This Personal Information aids PAP in administering PAP by: (i) processing this Application; (ii) verifying my information; (iii) identifying and/or determining eligibility under PAP and other patient assistance resources; (iv) investigating and verifying my insurance benefits; (v) coordinating the dispensing and delivery of medication; (vi) conducting additional services to run PAP; and (vii) conducting quality assurance and/or other internal business activities in connection with PAP. I (or my parent/guardian/legal representative) further give permission to PAP to use and disclose my (or the patient's) Personal Information to Health Care Providers, Insurer(s), caregivers, Novo Nordisk, its affiliates, service providers, and agents (collectively "Novo Nordisk"), for the purposes described above. I (or my parent/guardian/legal representative) understand and acknowledge that while PAP, Novo Nordisk, and any authorized contractors acting on their behalf will make every effort to keep Personal Information provides, and agents (collectively "Novo Nordisk"), for the purposes described above. I (or my parent/guardian/legal representative) acknowledge that once disclosed, Personal Information may be legally re-disclosed by federal privacy and security laws or applicable state laws. Specifically, I (or my parent/guardian/legal representative) acknowledge that once disclosed, Personal Information may be legally re-disclosed by authorized recipients unless otherwise prohibited by law. I (or my parent/guardian/legal representative) may also revoke (withdraw) this authorization at any time in the future by calling 1-866-310-7549 or writing to Novo Nordisk, Inc. PO Box 370, Somerville, NJ 08876. Such refusal or future revocation will not affect my (or the patient's) commencement or continuation of treatment by healthcare providers, pharmacies, service providers, insurer(By signing below, I acknowledge that I have read and agree to the Patient Authorization above.

I am signing on behalf of the patient, and I hereby affirm that I have the legal right to do so, that I am the parent or legal guardian of the patient, or that I otherwise have valid power of attorney to act on behalf of the patient.

SIGNATURE Patient or Legal Representative Signature*: Date*: **REQUIRED** Legal Representative: Relationship to patient: Phone:

Telephone Consumer Protection Act ("TCPA") Communication Consent

I (or my parent/guardian/legal representative) also agree to be contacted by PAP and others on its behalf by telephone calls made by or using an automated dialing system or pre-recorded messages at the number(s) provided in this Application, for all non-marketing purposes. I (or my parent/guardian/legal representative) understand that I (or my parent/guardian/legal representative) may be asked to provide my (or the patient's) zip code and date of birth during pre-recorded calls in order to verify my (or the patient's) identity and that this information will not be retained by PAP or its partners but is simply to verify identity. I (or my parent/guardian/legal representative) agree to notify PAP promptly if any of my numbers or addresses change in the future. I (or my parent/guardian/ legal representative) understand that this consent is not required, or a condition of purchase and it can be revoked at any time. I (or my parent/guardian/legal representative) further understand that I (or my parent/guardian/legal representative) can review the full Novo Nordisk Privacy Policy at https://www.novonordisk-us.com/privacy-notice.html.

By providing a phone number and signing below, I acknowledge that I have read and agree to the TCPA Communication Consent above.

Phone*:

Safety Information

If a safety concern is reported, I (or my parent/guardian/legal representative) give permission to share my personal information to Novo Nordisk, who may contact me with follow-up inquiries, and who may report my personal information to the health authorities to comply with applicable rules and regulations.

Program Authorization & Certification

I (or my parent/guardian/legal representative) hereby certify that I (or my parent/guardian/legal representative): (i) am over 18; (ii) am a United States citizen or legal resident; (iii) do not have the ability to pay for the medication(s) requested by my (or the patient's) health care provider on the attached prescription(s) and I meet the financial criteria detailed on this application to qualify for the program. I also certify that I am not enrolled in or eligible for any of the following: (i) Medicaid; (ii) Medicare Extra Help/Low Income Subsidy ("LIS"); (iii) federally funded insurance programs, with the exception of Medicaré Part D; or (iv) receive prescription drug benefits throughout the U.S. Veterans Administration, other than Medicare Part D. Patients enrolled in Medicare Part D who satisfy the exception or Medicare Part D. Patients enrolled in Medicare Part D who satisfy the financial eligibility criteria qualify for the program, but once enrolled, must stay in the program through the end of the calendar year. I certify that (i) all information provided in this application is true and correct and that I (or my parent/guardian/legal representative) will verify any of the information provided to PAP upon request; (ii) will verify my (or the patient's) application status and receipt of the indicated medication(s) upon request by PAP; (iii) if approved to participate in PAP, I (or my parent/guardian/legal representative) will not seek reimbursement for the medication(s) requested from any government program or third-party insurer; and (iv) will comply with any insurance carrier disclosure requirements, including my participation in PAP; (v) I (or my parent/guardian/legal representative) authorize PAP to contact me (or my parent/guardian/legal representative) by mail, email, and telephone (in accordance with the TCPA Communication Consent above) at the number(s), email(s), and address(es) provided on this application so that PAP can provide me with access to the products which I am prescribed.

I (or my parent/guardian/legal representative) understand and agree: (i) my eligibility to participate in PAP is subject to Novo Nordisk's decision and that Novo Nordisk may modify or terminate PAP at any time; (ii) I may be required to provide proof of ineligibility for certain other prescription drug coverage programs in order to meet the eligibility requirements for PAP; and (iii) I am required to report any changes to my health insurance and prescription drug coverage to PAP. I (or my parent/guardian/legal representative) understands that the product received through the PAP is provided to me free of charge and that I have no obligation to purchase the product due to my participation in the PAP. I (or my parent/guardian/legal representative) also give permission to PAP to combine or aggregate any information collected about me with information PAP may collect from other sources for the purpose of providing or administering PAP. In completing this Application, I confirm the following is complete and accurate and that I have read and agree to the Patient Authorization.

I am signing on behalf of the patient, and I hereby affirm that I have the legal right to do so, that I am the parent or legal guardiar	າ of the
patient, or that I otherwise have valid power of attorney to act on behalf of the patient.	

patient, or that rother wise have valid power of	i actorney to act on benan of the patient.			
Patient or Legal Representative Signature*:	Date*:	SIGNAT	TURE	
Legal Representative:	Relationship to patient:	Phone:	KEQ01	

Phone: 866-310-7549 M-F 8AM-8PM ET Novo Nordisk, Inc. PO Box 370 Somerville, NJ 08876 Fax# 866-441-4190

Patient First Name*:

Known Drug Allergies*:

Novo Nordisk Maine State Insulin Affordability Program

Last Name*:

Prescriber Information (All medication will be shipped to the prescriber. No PO Box permitted.)



PRESCRIBER SECTION

NovoLog® (insulin aspart) injection 100 U/mL

Insulin Aspart Injection 100 U/mL (UB)

insulin aspart injectable suspension) 100 U/mL

Novolin® R (insulin human injection) 100 U/mL

NovoFine® 32G 6mm (100 needles/box)

Zegalogue® (dasiglucagon) injection 0.6 mg/0.6 mL

human insulin injection) 100 U/mL

NovoLog® Mix 70/30 (insulin aspart protamine and

Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 100 U/mL (UB)

Novolin® N (isophane insulin human suspension) 100 U/mL

Novolin® 70/30 (human insulin isophane suspension and

Asterisks indicate required field. Do not leave blank.

Patient DOB*:

Vial

Vial

Vial

Vial

Vial

Vial

Vial

Auto-injector 1-pack

Prefilled Syringe 1-pack

FlexPen®

FlexPen®

FlexPen®

FlexPen®

Auto-injector 2-pack

Prefilled Syringe 2-pack

Cartridge

Cartridge

First Name*:		Last Name*:			Designa	tion*:		
Street Address*:								
Suite/Building/Floor#:								
City:				Stat	e:	Zip:		
Phone*:		State License N	lumber#*:			State Where	Licensed:	
Fax*:	Office Contact:		Office Er	nail:				
NPI*:	Days Office is Clo	sed for Deliver	ies:					
written. (Handwritten/valid electronic signatures accepted; no photocopies, power or attorney, or stamped signatures allowed) Health Care Practitioner Declaration: "My signature certifies that I am a licensed health care practitioner eligible under state law to prescribe, receive, and dispense the requested medication(s) listed on the attached order, shipped from Novo Nordisk, and that I am not prohibited from participating in federally funded health care programs. If I am a Nurse Practitioner, Physician Assistant, Pharmacist, or PharmD, I certify that I am authorized and eligible in the state within which I am currently practicing to prescribe, receive, and dispense these products, and that I have my supervising Physician's approval to do so if required by law. Note: Prescribing practitioner information must match practitioner's signature. I also certify that the product(s) being prescribed are to treat diagnosis(es) consistent with indication(s) and dosing described in the product's prescribing information. I further certify that all information provided in the Licensed Health Care Practitioner Information section is correct. I agree that medication(s) provided to me by Novo Nordisk for the applicant named in the Applicant Information section will be provided by me to such eligible applicant for his or her own use without charge. I will not otherwise use any of such medications or prescribe, provide or dispense all or any portion thereof for the use of any other person. I consent that Novo Nordisk may contact the applicant named in the Applicant Information section for verification of applicant status and receipt of the indicated medication(s). I further consent that Novo Nordisk may, at its discretion and with adequate notice, perform an on-site audit/review solely related to Novo Nordisk Diabetes Patient Assistance Program (PAP) records related to the applicant named above on this applicant in J understand that I am not eligible to seek reimbursement for any medication dispensed by PAP, from any government								
Rx		Max Dose/						
Product		Day (units)	Sig/Directions (e.g., QD, E	ID)	Formula	ation		Quantity
Fiasp® (insulin aspart) injection 1	100 U/mL				Vial	FlexTouch®	Cartridge	
Tresiba® (insulin degludec) injec	tion U-100				Vial	FlexTouch®		
Insulin Degludec Injection (U-100 (UB)				Vial	FlexTouch®	<u> </u>	
Tresiba® (insulin degludec) injec	ction U-200				FlexTo	ouch®		
Insulin Degludec Injection (U-200 (UB)				FlexTo	ouch®		

NovoPen Echo® 1 pen 1 pen 2 All orders will be filled with up to a **120-day** supply unless otherwise indicated by the prescriber. Prescribers, please complete the application with max daily

dose and sig accordingly.

FlexPen®/FlexTouch® come in 5 pen packages and are used with Novo Nordisk disposable needles. **Needles will not be sent as part of the Program order if they are not requested.**

UB=Unbranded Biologic. Unbranded Biologics of Novo Nordisk-branded analog insulins are available from Novo Nordisk Pharma, Inc. (NNPI)